Why Vera Therapeutics, Inc.’s (VERA) Stock Is Up 5.04%
As of Tuesday, October 27, Vera Therapeutics, Inc.’s VERA share price has surged by 5.04%, which has investors questioning if this is right time to sell.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Michael Rose
Cynthia McLaughlin
Jenna Brashear
Michael Rose
| Share Statistics | VERA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,840.0 | $203.5 | 55% |
|
| Shares Out (Mil) | 72.1 | 55.2 | 55% |
|
| Institutional Ownership | 99.1% | 93.3% | 84% |
|
| Float (Mil) | 49.3 | 40.4 | 46% |
|
| Beta | 1.19 | 1.05 | 69% |
|
| Avg Daily Volume (000s) | 1,248 | 569 | 73% |
|
| Price Change (52-week) |
(10.9%) | 38.8% | 44% |
|
| Growth | VERA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (41.2%) | (10.7%) | 9% |
|
| EPS (5yr) | 51.1% | 15.4% | 93 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (51.8%) | (15.7%) | 6% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 8 | 8 | |
| Current EPS | ($1.408) | ($5.952) | ($3.916) | |
| Month Ago EPS | ($1.541) | ($6.254) | ($4.251) | |
| # Rev Up | 0 | 2 | 1 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($1.568) | ($6.322) | ($4.414) | |
| Year/Year Chg | 8.4% | 27.6% | (86.4%) | |
| Financials | VERA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $10 | $40 | 9% |
|
| Net Income (TTM) (Mil) | ($415) | ($44) | 3% |
|
| EPS (TTM) | ($5.910) | ($1.400) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | ($376) | ($35) | 2% |
|
| Net Cash Flow (TTM) (Mil) | ($3) | $-0 | 39% |
|
| Long-Term Debt (Q1) (Mil) | $77 | $4 | 42% |
|
| Enterprise Value (Q1) (Mil) | $1,587 | $142 | 47% |
|
| Valuation | VERA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.52 | 1.96 | 85% |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | VERA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 67.9% | 67.6% | 80% |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (84.5%) | (47.0%) | 6% |
|
| ROE | (113.5%) | (51.8%) | 8% |
|
| Liabilities to Assets | 28.5% | 29.6% | 20% |
|
| F-Score | 2 | 3 | 7% |
|
Vera Therapeutics, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors